Practice patterns and outcomes of percutaneous coronary interventions in the United States: 1995 to 1997

被引:38
作者
Lauer, MA
Karweit, JA
Cascade, EF
Lin, ND
Topol, EJ
机构
[1] Borgess Heart Inst, Kalamazoo, MI 49048 USA
[2] Lewin Grp, Alexandria, VA USA
[3] Cleveland Clin Fdn, Cleveland, OH 44195 USA
关键词
D O I
10.1016/S0002-9149(02)02240-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Randomized trials have demonstrated the superiority of coronary stents in combination with a platelet-focused pharmacologic approach in percutaneous coronary intervention (PCI). However, nationally representative data examining the impact of these technologies on patient outcomes and costs remain scarce. This study sought to determine the real-world impact of changes in the use of stents and anticoagulant agents in PCI on outcomes and costs. A nationally representative sample of 37,088 patients who underwent PCI from October 1995 to October 1997 was identified from in-patient hospital claims data acquired from HCIASachs. Utilization of coronary stents, antiplatelet and anticoagulant agents, and outcome measurements of in-hospital death, coronary artery bypass grafting (CABG), repeat PCI, bleeding, and costs were analyzed in 6-month intervals. Acute events (death, urgent CABG, or PCI) decreased (p < 0.001), whereas use of stents, abcixmab or both, increased (p < 0.001). Dosages of heparin and bleeding complications declined significantly (p < 0.001) over the 2-year period. Heparin dosages were higher in patients who experienced bleeding or death than in those who did not (p < 0.001). The average hospital length of stay decreased significantly (p < 0.001), largely driven by a reduction in time between the procedure and hospital discharge. By the end of the study period, bleeding was the most frequent (5.5%) complication of PCI and was associated with considerable costs, adding $10,225 to baseline costs. (C) 2002 by Excerpta Medica, Inc.
引用
收藏
页码:924 / 929
页数:6
相关论文
共 14 条
[11]   A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents [J].
Schomig, A ;
Neumann, FJ ;
Kastrati, A ;
Schuhlen, H ;
Blasini, R ;
Hadamitzky, M ;
Walter, H ;
ZitzmannRoth, EM ;
Richardt, G ;
Alt, E ;
Schmitt, C ;
Ulm, K .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (17) :1084-1089
[12]   A COMPARISON OF BALLOON-EXPANDABLE-STENT IMPLANTATION WITH BALLOON ANGIOPLASTY IN PATIENTS WITH CORONARY-ARTERY DISEASE [J].
SERRUYS, PW ;
DEJAEGERE, P ;
KIEMENEIJ, F ;
MACAYA, C ;
RUTSCH, W ;
HEYNDRICKX, G ;
EMANUELSSON, H ;
MARCO, J ;
LEGRAND, V ;
MATERNE, P ;
BELARDI, J ;
SIGWART, U ;
COLOMBO, A ;
GOY, JJ ;
VANDENHEUVEL, P ;
DELCAN, J ;
MOREL, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (08) :489-495
[13]   Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade [J].
Topol, EJ ;
Lincoff, AM ;
Califf, RM ;
Tcheng, JE ;
Kleiman, NS ;
Adelman, AG ;
Burton, JR ;
Talley, JD ;
Ivanhoe, RJ ;
Ducas, C ;
Cheung, PK ;
Schick, U ;
Badard, D ;
Kramer, J ;
Leary, J ;
Snyder, H ;
Wilson, R ;
Dearen, M ;
Caramori, P ;
Webber, S ;
Taylor, J ;
Ferrando, T ;
Cohen, E ;
Balleza, L ;
Rouse, C ;
Hogg, N ;
Kelly, T ;
Alston, S ;
Webb, J ;
Buller, E ;
Ricci, DR ;
Mockman, S ;
Tanguay, JF ;
Poitras, AM ;
Timis, G ;
Davey, D ;
Coleman, P ;
Herrold-Runge, P ;
O'Neill, BJ ;
Foshey, K ;
Fitzgerald, N ;
Almond, D ;
Kostuk, W ;
White, J ;
Oskalns, R ;
Gottlieb, R ;
Koren, P ;
Palazzo, D ;
Azrin, M ;
Barry, MB .
LANCET, 1998, 352 (9122) :87-92
[14]  
Topol EJ, 1997, NEW ENGL J MED, V336, P1689